219 related articles for article (PubMed ID: 34673001)
21. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Yang Y; Wang K; Chen H; Feng Z
Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
[TBL] [Abstract][Full Text] [Related]
22. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
23. SAR study of small molecule inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
Kawashita S; Aoyagi K; Fukushima K; Hantani R; Naruoka S; Tanimoto A; Hori Y; Toyonaga Y; Yamanaka H; Miyazaki S; Hantani Y
Chem Biol Drug Des; 2021 Nov; 98(5):914-929. PubMed ID: 34495575
[TBL] [Abstract][Full Text] [Related]
24. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
[TBL] [Abstract][Full Text] [Related]
25. Computational design of PD-L1 small molecule inhibitors for cancer therapy.
Chandrasekaran J; Elumalai S; Murugesan V; Kunjiappan S; Pavadai P; Theivendren P
Mol Divers; 2023 Aug; 27(4):1633-1644. PubMed ID: 36006501
[TBL] [Abstract][Full Text] [Related]
26. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
Molecules; 2019 May; 24(11):. PubMed ID: 31151293
[TBL] [Abstract][Full Text] [Related]
27. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
[TBL] [Abstract][Full Text] [Related]
28. Virtual Screening and In Vitro Evaluation of PD-1 Dimer Stabilizers for Uncoupling PD-1/PD-L1 Interaction from Natural Products.
Lung J; Hung MS; Lin YC; Hung CH; Chen CC; Lee KD; Tsai YH
Molecules; 2020 Nov; 25(22):. PubMed ID: 33202823
[TBL] [Abstract][Full Text] [Related]
29. Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer.
Bailly C; Vergoten G
Biochem Pharmacol; 2020 Aug; 178():114042. PubMed ID: 32445869
[TBL] [Abstract][Full Text] [Related]
30. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
31. Identification of a PD1/PD-L1 inhibitor by structure-based pharmacophore modelling, virtual screening, molecular docking and biological evaluation.
Choorakottayil Pushkaran A; K K; T AM; Biswas R; Mohan CG
Mol Inform; 2023 Jun; 42(6):e2200254. PubMed ID: 36897739
[TBL] [Abstract][Full Text] [Related]
32. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, ADMET, and Molecular Dynamics (MD) Simulation of Potential Inhibitors of PD-L1 from the Library of Marine Natural Products.
Luo L; Zhong A; Wang Q; Zheng T
Mar Drugs; 2021 Dec; 20(1):. PubMed ID: 35049884
[TBL] [Abstract][Full Text] [Related]
33. In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction.
Lu CH; Chung WM; Tsai CH; Cheng JC; Hsu KC; Tzeng HE
Sci Rep; 2022 Jan; 12(1):303. PubMed ID: 34996924
[TBL] [Abstract][Full Text] [Related]
34. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
[TBL] [Abstract][Full Text] [Related]
35. Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach.
Paciotti R; Agamennone M; Coletti C; Storchi L
J Comput Aided Mol Des; 2020 Aug; 34(8):897-914. PubMed ID: 32185582
[TBL] [Abstract][Full Text] [Related]
36. Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation.
Liang J; Wang B; Yang Y; Liu B; Jin Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674800
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations.
Sun X; Yan X; Zhuo W; Gu J; Zuo K; Liu W; Liang L; Gan Y; He G; Wan H; Gou X; Shi H; Hu J
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29986511
[TBL] [Abstract][Full Text] [Related]
38. Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction.
Kawashita S; Aoyagi K; Yamanaka H; Hantani R; Naruoka S; Tanimoto A; Hori Y; Toyonaga Y; Fukushima K; Miyazaki S; Hantani Y
Bioorg Med Chem Lett; 2019 Sep; 29(17):2464-2467. PubMed ID: 31351692
[TBL] [Abstract][Full Text] [Related]
39. The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study.
Ahmed M; Barakat K
Biochemistry; 2017 Oct; 56(40):5428-5439. PubMed ID: 28898057
[TBL] [Abstract][Full Text] [Related]
40. Insights into small molecule inhibitor bindings to PD-L1 with residue-specific binding free energy calculation.
Xia W; He L; Bao J; Qi Y; Zhang JZH
J Biomol Struct Dyn; 2022; 40(22):12277-12285. PubMed ID: 34486939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
